ArticleBMC psychiatry2025
Treatment persistence and modification patterns of SSRIs in children and adolescents with depression: a nationwide population-based study in South Korea.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-World Antidepressant Treatment Persistence in Children and Adolescents with Major Depressive Disorder in Japan: A Retrospective Nationwide Claims-Based Study.Neuropsychiatric disease and treatment · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThis study aimed to evaluate the persistence and treatment modification patterns of three commonly used selective serotonin reuptake inhibitors (SSRIs)-fluoxetine, escitalopram, and sertraline-in children and adolescents with depression.
methodsWe conducted a nationwide population-based retrospective cohort study using the Health Insurance Review and Assessment Service database of South Korea (2007-2019). Patients aged 5-19 years who were newly prescribed one of three SSRIs between 2009 and 2018 were included. During a one-year follow-up period, we assessed treatment persistence and categorized treatment changes as simple discontinuation, switching, combination with another antidepressant, and augmentation with antipsychotics. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated via Cox proportional hazards models.
resultsOnly approximately 3% of patients remained on their initial SSRIs after one year, with most treatment changes occurring due to simple discontinuation, followed by switching, augmentation, and combination. Fluoxetine was associated with the lowest risk of treatment modification, particularly for combination and augmentation. The lowest switching rates were associated with escitalopram, whereas the lowest risk of simple discontinuation was associated with sertraline. Sociodemographic and clinical factors, including psychiatric comorbidities, significantly influence treatment patterns.
conclusionsEach SSRI exhibited distinct patterns of treatment modifications, with no single agent consistently outperforming the other agents. These findings highlight the need for individualized SSRI selection that considers both pharmacological profiles and patient characteristics in the real-world management of pediatric depression. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.